Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
hal.structure.identifierInstitut de Mécanique et d'Ingénierie de Bordeaux [I2M]
dc.contributor.authorAUFFRAY, Julie
IDREF: 256072906
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorBITEAU, Nicolas
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorCAYREL, Anne
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorDACHEUX, Denis
IDREF: 230332838
hal.structure.identifierInstitut de Mécanique et d'Ingénierie de Bordeaux [I2M]
dc.contributor.authorHSEIN, Hassana
hal.structure.identifierInstitut de Mécanique et d'Ingénierie de Bordeaux [I2M]
dc.contributor.authorTCHORELOFF, Pierre
IDREF: 069233624
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorNOEL, Thierry
dc.date.accessioned2025-10-16T07:21:49Z
dc.date.available2025-10-16T07:21:49Z
dc.date.issued2025-12-01
dc.identifier.issn2150-5608en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/207827
dc.description.abstractEnVulvovaginal candidiasis (VVC) is a prevalent fungal infection primarily caused by the opportunistic pathogen . Among women affected by VVC, up to 8% experience more than four episodes per year, regarded as recurrent vulvovaginal candidiasis (RVVC). Current treatments for VVC are effective for isolated episodes but are insufficient for preventing recurrences, highlighting the need to develop novel treatments for the management of RVVC. In this study, we explore passive immunization as a potential alternative strategy to prevent VVC. The Candidalysin toxin (Cdlys) and the parietal protein Hyr1, specifically expressed by the infectious hyphal form of , were selected as targets for murine mAbs development. Anti-Cdlys and anti-Hyr mAbs were produced using the hybridoma technology and were first selected for their antigenic specificity and high affinity. The anti-Hyr1 mAb 4F3.2.1 was then selected for its efficient opsonophagocytic activity with murine macrophages, while the anti-Cdlys mAb 5E2.2.1 was selected for its strong ability to neutralize the cytolytic and pro-inflammatory effects of Candidalysin. The prophylactic activity of the mAbs was then evaluated in a murine model of VVC. Results demonstrated that intravaginal administration of the combined mAbs confered protection against the development of the infection, significantly reducing fungal colonization and inflammation in the vaginal environment. These findings highlight the putative efficacy of passive mucosal immunization with anti-Cdlys and anti-Hyr1 mAbs in preventing VVC, providing a strong proof of concept for their potential as novel therapeutic strategy in the management of RVVC.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAnimals
dc.subject.enCandidiasis
dc.subject.enVulvovaginal
dc.subject.enFemale
dc.subject.enImmunization
dc.subject.enPassive
dc.subject.enMice
dc.subject.enAntibodies
dc.subject.enMonoclonal
dc.subject.enCandida albicans
dc.subject.enFungal Proteins
dc.subject.enMice
dc.subject.enInbred BALB C
dc.subject.enAntibodies
dc.subject.enFungal
dc.subject.enDisease Models
dc.subject.enAnimal
dc.subject.enImmunity
dc.subject.enMucosal
dc.title.enMucosal passive immunization with monoclonal antibodies targeting Candidalysin and Hyr proteins attenuates vaginal candidiasis in mice.
dc.title.alternativeVirulenceen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/21505594.2025.2569629en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
dc.identifier.pubmed41069059en_US
bordeaux.journalVirulenceen_US
bordeaux.page2569629en_US
bordeaux.volume16en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue1en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-05317110
hal.version1
hal.date.transferred2025-10-16T07:21:52Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Virulence&rft.date=2025-12-01&rft.volume=16&rft.issue=1&rft.spage=2569629&rft.epage=2569629&rft.eissn=2150-5608&rft.issn=2150-5608&rft.au=AUFFRAY,%20Julie&BITEAU,%20Nicolas&CAYREL,%20Anne&DACHEUX,%20Denis&HSEIN,%20Hassana&rft.genre=article


Archivos en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem